• BetterLife Pharma signed an agreement with Syner-G BioPharma Group to oversee GMP manufacturing of BETR-001 for a planned IND filing.
• The work supports a Phase 1 program targeted to start in Q1 2027 as BETR-001 completes final IND-enabling studies.
• BETR-001, a non-hallucinogenic LSD derivative, is being developed initially for chronic cluster headache and chronic migraine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.